EHL BIO Receives Prestigious Award from the Ministry of Health and Welfare

A Milestone Achievement in Regenerative Medicine

EHL BIO has officially been selected as a recipient of the 2024 Minister of Health and Welfare Award, a prestigious honor granted to entities that have made significant contributions to the field of Advanced Regenerative Medicine in the Republic of Korea. This milestone is a result of the dedicated efforts of over 85 research personnel working under international standards to develop therapeutic solutions that enhance patients' quality of life.

Receiving this award serves as a testament to EHL BIO's potential as a leader in biotechnology, particularly in developing new-generation biological drugs. This recognition acts as a vital catalyst for the company to continue advancing cell therapy until it reaches successful clinical implementation and becomes a new standard in the near future.

KDSTEM: Nationally Acclaimed Innovation

The primary factor leading to this prestigious award is the development of 'KDSTEM,' an autologous urine-derived stem cell product designed for chronic kidney disease management. This technology represents a significant breakthrough, as it utilizes cells originating directly from the kidney, which possess the capability to secrete the Klotho protein—a factor that substantially helps reduce oxidative stress and supports renal tissue restoration according to EHL team evaluations.

Beyond its efficacy, KDSTEM stands out for its non-invasive collection method. This provides patients with convenience. Currently, this project is also supported by government funding under the Ministry's technology development program for regenerative medicine in Korea to drive clinical trials toward the next stages steadily.

The Minister of Health and Welfare Award is a testament to our unwavering commitment to research that establishes new standards for regenerative medicine.

GMP Standards and Global Confidence

EHL BIO's success extends beyond research to include a manufacturing process of the highest standards. The company's research center and production facilities operate under GMP (Good Manufacturing Practices) standards, featuring Class 100 cleanroom facilities and a cell storage system in liquid nitrogen at -196°C to ensure excellent cell viability. This production system supports a capacity of up to 6,000 lots per year, enabling the continuous R&D of products like KDSTEM.

Furthermore, EHL BIO is the first in Korea to be authorized for Human Cell Management Business under the Advanced Regenerative Bio Act. This reinforces a cell management system that is systematic, transparent, and provides high-quality standards for patients.

Moving Forward Toward Global Leadership

MD Hong-gi Lee, CEO of EHL BIO, stated upon receiving the award that this ministerial recognition serves as a reminder of the mission to support physical recovery from complex diseases. The company's research and development focus not only on chronic kidney disease but also cover Atopic Dermatitis (ADSTEM), which is entering Phase 3 clinical trials, as well as osteoarthritis and other neurological conditions, aiming for life extension and quality living (Aging Well).

With a cooperative network of partner hospitals in South Korea, EHL BIO is ready to deliver these cutting-edge medical innovations. The EHL Thailand team is also prepared to facilitate coordination to bring expertise from Korea to those interested in physical restoration through international-standard stem cell technology.